The treatment of severe malaria

被引：25

作者：

Dondorp, Arjen M.

Day, Nick P. J.

机构：

[1] Mahidol Univ, Fac Trop Med, Wellcome Trust, Bangkok 10400, Thailand

[2] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Ctr Trop Med, Oxford OX3 9DU, England

来源：

TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE | 2007年 / 101卷 / 07期

基金：

英国惠康基金;

关键词：

severe malaria; treatment; antimalarials; artesunate; suppositories; mortality;

D O I：

10.1016/j.trstmh.2007.03.011

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

In the SEAQUAMAT trial, parenteral artesunate was shown to be associated with a considerably lower mortality than quinine, and is now the recommended treatment for severe malaria in low-transmission areas and in the second and third trimesters of pregnancy. A trial is underway to establish its rote in African children. The development of artesunate suppositories may provide the means to treat patients with severe disease in remote rural settings, potentially buying the time needed to reach a health care facility. The increasing availability of basic intensive care facilities in developing countries also has the potential to further reduce mortality. (C) 2007 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.

引用

页码：633 / 634

页数：2

共 5 条

[1] Efficacy of rectal artesunate compared with parenteral quinine in initial treatment of moderately severe malaria in African children and adults: a randomised study [J].